PIPELINE
Elraglusib Injection — Adult (Actuate-1801)
Study
PHASE 1
PHASE 2
PHASE 3
ANITICIPATED MILESTONES
Part 1 and 2: Dose Escalation
Refractory Cancers
PHASE 1
PHASE 2
PHASE 3
Fully enrolled
Published Carneiro et al. 2024
Part 3A: Pancreatic Cancer (combined with GnP)
1st line metastatic (single arm)
PHASE 1
PHASE 2
PHASE 3
Fully enrolled
Submitted for publication
Part 3B: Pancreatic Cancer (combined with GnP)
1st line metastatic (randomized, controlled)
Fast track designation
Fast track designation
PHASE 1
PHASE 2
PHASE 3
Fully enrolled
Interim Analysis: Mid-2024
Topline Data – 1Q25
Topline Data – 1Q25
Elraglusib Injection — Pediatric (Actuate-1902)
Phase 1: Dose Escalation
Solid cancers refractory (combined with chemo)
PHASE 1
PHASE 2
PHASE 3
Fully enrolled
Study Completion - 2H25
Phase 2: Ewing Sarcoma
(combined with cyclophosphamide/topotecan) single arm, exploratory
PHASE 1
PHASE 2
PHASE 3
Initial Data - 2H25
Elraglusib Oral Tablet — Adult (Actuate-2401)
Phase 1:
• Advanced, refractory solid cancers
In Planning
FPFD - 2H24
RP2D- 1H25
RP2D- 1H25
Phase 2:
• Melanoma (metastatic, CPI refractory)
In Planning
Topline Data - 1H26
• Colorectal cancer (metastatic, refractory)
In Planning
TBD
Elraglusib Oral Tablet — Pediatric
Phase 1:
• Advanced, refractory cancer
(solid and hematological)
(solid and hematological)
In Planning
TBD
Company Sponsored Study
Initiating
GnP: gemcitabine/nab-paclitaxel
FPFD: First patient first dose
RP2D: Recommended Phase 2 Dose
FPFD: First patient first dose
RP2D: Recommended Phase 2 Dose
CLINICAL TRIALS
If you or a loved one are living with cancer, and you’re interested in learning about our clinical trials we currently have open, click below to learn more.